- Home
- RERE vs GERN Comparison
RERE vs GERN Comparison
Compare RERE & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RERE | GERN |
|---|---|---|
| Founded | 2011 | 1990 |
| Country | China | United States |
| Employees | N/A | 258 |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 996.7M | 821.1M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | RERE | GERN |
|---|---|---|
| Price | $4.68 | $1.26 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $2.17 |
| AVG Volume (30 Days) | 970.3K | ★ 14.2M |
| Earning Date | 05-19-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.27% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $25.70 | $26.91 |
| Revenue Next Year | $22.93 | $43.75 |
| P/E Ratio | $34.57 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.41 | $1.04 |
| 52 Week High | $6.47 | $2.01 |
Technical Indicators
Market Signals| Indicator | RERE | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 49.16 | 32.94 |
| Support Level | $4.27 | $1.24 |
| Resistance Level | $4.87 | $1.29 |
| Average True Range (ATR) | 0.27 | 0.09 |
| MACD | 0.05 | -0.02 |
| Stochastic Oscillator | 41.67 | 10.42 |
Price Performance
Historical ComparisonAbout RERE ATRenew Inc.
ATRenew Inc is a pre-owned consumer electronics transactions and services platform in China. The majority of its revenue is derived from online product sales of phones and other consumer electronics goods through its platforms PJT Marketplace and Paipai Marketplace. The Company's principal operations and geographic markets are in the People's Republic of China.
About GERN Geron Corporation
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.